Oxurion.com

Oxurion.com has Server used 46.137.165.193 IP Address with Hostname in Ireland. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2017-12-08 (2 years, 46 days) and hosted in Dublin Ireland, server ping response time 103 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Oxurion keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Oxurion
2 Oxurion nv
3 Oxurion koers
4 Oxurion beursig
5 Oxurion in nj
6 Oxurion share price
7 Oxurion nj
8 Oxurion dme
9 Oxurion cours

Hosting Provider

Website: Oxurion.com
Hostname: ec2-46-137-165-193.eu-west-1.compute.amazonaws.com
Country:
Region: 07
City: Dublin
Latitude: 53.333099365234
Longitude: -6.248899936676
Area Code: 0
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   » Bostonhomecarellc.com (8 seconds ago)

   » Thebikecompany.net (14 seconds ago)

   » Ypacarts.com (3 seconds ago)

   » Oxurion.com (0 seconds ago)

   » Ameriplusonline.net (1 seconds ago)

   » 500150.com (4 seconds ago)

   » Pswood.com (27 seconds ago)

   » Btmkorea.com (29 seconds ago)

   » Africanbusinesscentral.com (2 seconds ago)

Results For Websites Listing

Found 59 Websites with content related to this domain, It is result after search with search engine

Oxurion — Advancing Science. Enhancing Vision | Oxurion

(3 day ago) Oxurion is listed on Euronext Brussels under the symbol OXUR. Check our Investors pages to find more information about extraordinary and annual shareholders meetings and learn more about the full year results, half year results and business reviews by Oxurion, or download our publications and reports. Read more

https://www.oxurion.com/

DA: 15 PA: 15 MOZ Rank: 16

| live

(11 day ago) Oxurion NV - Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presente 08/05/2019 Oxurion NV : Oxurion NV Business Update - Q1 2019 24/04/2019 Oxurion NV announces full enrollment in its Phase 1 trial evaluating the safety of its plasma kal

https://live.euronext.com/nl/product/equities/BE0003846632-XBRU

DA: 17 PA: 38 MOZ Rank: 55

OXURION (OXUR.BR) Stock Price, Quote, History & News

(3 day ago) Imagine Owning Oxurion (EBR:OXUR) While The Price Tanked 59%. Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly.

https://finance.yahoo.com/quote/OXUR.BR/

DA: 17 PA: 15 MOZ Rank: 32

OXURION NV : Cours Action Bourse | OXUR | BE0003846632

(7 years ago) Oxurion (ex ThromboGenics) est spécialisé dans la recherche et le développement de produits bio-thérapeutiques destinés au traitement des maladies cardiovasculaires, des troubles ophtalmiques

https://www.zonebourse.com/OXURION-NV-29715/

DA: 18 PA: 18 MOZ Rank: 36

Oxurion NV - Company Profile and News - Bloomberg Markets

(11 day ago) Company profile page for Oxurion NV including stock price, company news, press releases, executives, board members, and contact information

https://www.bloomberg.com/profile/company/OXUR:BB

DA: 17 PA: 24 MOZ Rank: 41

OXUR Stock Price | Oxurion N.V. Stock Quote (Belgium

(1 month ago) Oxurion N.V. Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA brand name.

https://www.marketwatch.com/investing/stock/oxur?countrycode=be

DA: 19 PA: 21 MOZ Rank: 40

OXURION » Koers (Aandeel) | Beursduivel.be

(3 day ago) Beleggen in OXURION (Aandeel, BRU). Alle beleggingsinformatie op een rij: Beurskoers, dividenden, technische analyse, fundamentele analyse, beursagenda, nieuws

https://www.beursduivel.be/Aandeel-Koers/60191463/OXURION.aspx

DA: 18 PA: 36 MOZ Rank: 54

OXUR:EN Brussels Stock Quote - Oxurion NV - Bloomberg Markets

(2 month ago) Oxurion NV: Oxurion Completes Enrolment of Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Sep 4, 2019 Oxurion NV: Oxurion to make a late-breaker presentation

https://www.bloomberg.com/quote/OXUR:BB

DA: 17 PA: 14 MOZ Rank: 31

home - Perspectives

(12 day ago) Oxurion NV Partners with Prevent Blindness to Educate Public on Diabetes-related Eye Disease. Both Oxurion and Prevent Blindness join forces during November to educate the public on risk factors, symptoms, treatment options, and financial assistance resources.

https://perspectives.oxurion.com/

DA: 24 PA: 24 MOZ Rank: 25

Recently Analyzed Sites